Tech Company Financing Transactions
Blue Note Therapeutics Funding Round
AVG Ventures, JAZZ Venture Partners and Memorial Sloan Kettering Cancer Center participated in a $5.2 million Series A funding round for Blue Note Therapeutics. The round closed on 9/13/2021.
Transaction Overview
Company Name
Announced On
9/13/2021
Transaction Type
Venture Equity
Amount
$5,200,000
Round
Series A
Proceeds Purpose
The additional proceeds will strengthen the company's capacity to develop evidence-based therapeutics.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
548 Market St. 55709
San Francisco, CA 94104
USA
San Francisco, CA 94104
USA
Phone
Website
Email Address
Overview
Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoffrey Eich
VP - Engineering
Timothy Clark
VP - Finance
Mark Elfers
VP - Human Resources
George Romanko
VP - Product Management
Michael McKinley
Browse more venture capital transactions:
Prev: 9/13/2021: Nectero Medical venture capital transaction
Next: 9/13/2021: Wisetack venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs